- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
COVID-19: Panacea Biotec sees production of 1 billion doses of vaccine candidate in 2022
The company has production targets of 500 million doses for 2021 and one billion doses in 2022 for its COVID-19 vaccine candidate, Panacea said in an emailed statement.
Bengaluru: Indian biotech firm Panacea Biotec Ltd said on Wednesday it remains on schedule to produce first production quantities of COVID-19 vaccine candidate by January 2021.The company has production targets of 500 million doses for 2021 and one billion doses in 2022 for its COVID-19 vaccine candidate, Panacea said in an emailed statement to Reuters.Last month, Panacea Biotec had advanced...
Bengaluru: Indian biotech firm Panacea Biotec Ltd said on Wednesday it remains on schedule to produce first production quantities of COVID-19 vaccine candidate by January 2021.
The company has production targets of 500 million doses for 2021 and one billion doses in 2022 for its COVID-19 vaccine candidate, Panacea said in an emailed statement to Reuters.
Last month, Panacea Biotec had advanced its response to address the unprecedented challenges of COVID-19 by collaborating with Refana Inc. USA to make COVID-19 vaccine widely accessible around the world in an equitable manner through a Joint Venture company to be based in Ireland. The collaboration aims to bring to patients a whole inactivated virus-based vaccine for COVID-19.
Read also: Panacea Biotec, Refana enter landmark collaboration for COVID-19 Vaccine
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751